Last updated: April 23, 2026
Pitavastatin calcium is typically supplied through a split chain: (1) API manufacturers that produce pitavastatin active pharmaceutical ingredient, then convert it to the calcium salt form; and (2) finished-dose manufacturers that buy API and formulate tablets. The practical supplier list for procurement usually starts at the API level (to control grade, polymorph, and salt form) and then adds finished-dose suppliers where needed.
Who supplies pitavastatin calcium as API or calcium-salt API?
Pitavastatin calcium is widely marketed as a generic API across multiple jurisdictions. Supplier coverage generally includes:
- API manufacturers producing pitavastatin and supplying the calcium salt form (pitavastatin calcium) for US/EU/ROW registrations
- Specialty chemical and pharmaceutical ingredient traders that distribute pitavastatin calcium API sourced from primary manufacturers
- Contract manufacturers that offer salt formation and re-crystallization services to lock the calcium form and targeted specs
Because “suppliers” depends on whether you buy API (pitavastatin calcium) or finished tablets (brands/generics), the operational supplier map splits into two procurement lanes:
Procurement lane A: Pitavastatin calcium API (for makers of tablets/capsules)
Common supplier categories you will see in tenders and DMF dossiers:
- Direct API manufacturers: typically hold the DMF/ASMF, with validated polymorph and particle-size control ranges and supported analytical methods.
- CMO/CMR salt-form and solid-state providers: support crystallization, desolvation, and polymorph control for the calcium salt.
- Distributors: list multiple sources, often faster lead times and documentation packaging (COA, CoC, chain-of-custody), but fewer direct controls over crystallization steps.
Procurement lane B: Finished pitavastatin calcium tablets (for wholesalers/importers and pharmacy channels)
Common supplier categories:
- ANDA/MAH generic manufacturers that file the tablet dossier and supply finished product
- Labeler/marketers that own the national MA/ANDA while sourcing finished product from one or more contract manufacturing sites
What supplier datasets should be used to identify approved manufacturers?
High-confidence supplier identification uses regulatory and commercial documentation that ties product form, salt form, and quality system to a specific manufacturer.
For API sourcing and quality assurance, the highest-signal databases are:
- FDA’s Drug Master Files (DMFs): identifies sites and API form supported in US filings (API-level traceability).
- EMA/Europe orphan and centralized submissions aren’t API-indexed the same way, but EU market authorizations and CEP routes often reveal manufacturing sites.
- US/Global inspection records: FDA facility inspection classification and outcomes help screen manufacturing reliability.
- Public COA and specification availability: vendors that can provide method summaries, impurity profiles, and salt-form confirmation have higher execution reliability.
For finished-dose sourcing:
- US ANDA/505(j) approvals: list applicants and label holders, which identifies the responsible manufacturer chain.
- EU national marketing authorizations: list MAH and manufacturing site(s).
Which types of companies actually sell pitavastatin calcium commercially?
Commercial pitavastatin calcium supply typically comes from three company archetypes:
-
Large, multi-product API houses
- Produce broad statin portfolios.
- Support multiple grades (for regulated markets vs general chemical grade, where applicable).
- Provide documentation aligned to DMF/ASMF expectations.
-
Statins-focused and chiral chemistry specialists
- Build the synthesis route and solid-state control around chiral statin intermediates and final salt conversion.
- Often market stronger polymorph and particle-size control statements.
-
Trading and distribution companies
- Provide “ready-to-ship” supply.
- Often act as a relay across multiple origin factories.
- Suitable for speed, but procurement teams still need to verify the actual origin factory, DMF/ASMF linkage, and salt-form evidence.
What specs and documentation define a pitavastatin calcium supplier in practice?
Procurement and quality teams typically evaluate suppliers against a consistent set of deliverables:
Core documentation to require from a pitavastatin calcium supplier
- COA including assay, impurities, and residual solvents (as specified by the relevant regulatory/contract requirements)
- Salt-form confirmation (pitavastatin calcium) using appropriate solid-state methods (e.g., XRPD, DSC)
- Polymorph / crystal form statement tied to specification (if the supplier markets a defined form)
- Impurity profile aligned to your regulatory expectation (e.g., threshold levels and identification status)
- Method summaries or references to compendial/non-compendial methods used for release testing
Operational manufacturing capabilities that separate strong suppliers
- Controlled crystallization and re-crystallization steps for calcium salt consistency
- Particle size control and defined PSD ranges when needed for tablet content uniformity
- Validated drying/desolvation process controls to manage water/hydrate risk
- Supply continuity through multi-site manufacturing or validated backup sites
Supplier landscape: pitavastatin calcium is widely distributed but must be origin-verified
Because many sellers list the chemical name “pitavastatin calcium” without tying it to a single manufacturing site, procurement should treat the supplier as two distinct things:
- Sales entity (what you sign with)
- Manufacturing origin (where the API actually gets made, dried, crystallized, and tested)
In statin API sourcing, origin verification is frequently the difference between:
- Consistent impurity profile and salt-form behavior across lots, versus
- Lot-to-lot variation that can trigger formulation or regulatory friction
Finished-dose suppliers vs API suppliers: how to choose the right channel
If you need tablets for commercialization or distribution
You need a finished-dose MAH/manufacturer chain, not just an API supplier:
- Tablet dissolution and stability depend on formulation excipients, granulation, compression, and coating parameters
- Your release specs, shelf-life extension, and packaging configurations depend on the finished product manufacturer
If you need API for internal formulation
API suppliers must support:
- Your required specification set for impurities and solid-state form
- Batch-to-batch consistency in salt formation and particle properties
Key procurement actions that reduce supplier failure modes
- Lock pitavastatin calcium salt-form evidence in the purchase order and quality agreement.
- Require supplier to name the manufacturing site(s) responsible for salt formation and final API release.
- Tie impurity reporting to your target spec using a defined impurity table and reporting levels.
- Confirm polymorph/crystal form control using XRPD/DSC-linked acceptance criteria.
- Run incoming quality controls to validate the supplier’s historical COA accuracy against your release tests.
Key Takeaways
- Pitavastatin calcium supply is best handled by separating API origin manufacturers from distributors, and separately mapping finished-dose tablet manufacturers if you need product rather than API.
- High-confidence supplier selection depends on documented salt-form confirmation, impurity profile alignment, and manufacturing site traceability tied to DMF/ASMF or regulatory submissions.
- Supplier lists that only name “pitavastatin calcium” sellers without origin factory and solid-state evidence frequently fail on quality execution.
FAQs
1) What is the difference between pitavastatin and pitavastatin calcium in sourcing?
Pitavastatin is the free base, while pitavastatin calcium is a defined calcium salt form. Your quality spec and solid-state confirmation should match the calcium salt to avoid salt-form mismatch in formulation and stability.
2) Should we buy pitavastatin calcium from API manufacturers or distributors?
For regulatory and quality control, direct API manufacturers are typically preferred because they provide clearer site traceability and stronger linkage to solid-state controls. Distributors can work for speed but require verified origin manufacturing details.
3) What documents should a pitavastatin calcium supplier provide with each lot?
A COA with assay and impurities, residual solvent data (if applicable), and solid-state/salt-form confirmation evidence are the baseline. Your contract should define the required tests and acceptance criteria.
4) Why do polymorph and crystal form matter for pitavastatin calcium?
Crystal form and salt form can change dissolution behavior and stability, affecting tablet performance and regulatory consistency. Suppliers that can lock acceptance criteria with XRPD/DSC evidence reduce risk.
5) How do we determine whether a supplier is suitable for regulated markets?
Use regulatory traceability: DMF/ASMF linkage for API or ANDA/MAH chain for tablets, plus inspection history and documented quality systems. Supplier capability should be demonstrated through lot documentation consistent with your spec.
References
[1] FDA. “Drug Master Files (DMF).” U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/dmf/
